Status:

COMPLETED

Timing and Duration of Acute Hepatitis C Treatment

Lead Sponsor:

Ain Shams University

Collaborating Sponsors:

University Hospital Freiburg

Beth Israel Deaconess Medical Center

Conditions:

Hepatitis C

Eligibility:

All Genders

18-50 years

Phase:

PHASE4

Brief Summary

Spontaneous resolution of acute hepatitis C infection cannot be predicted and the majority of cases persist and become chronic. This randomized trial assesses the efficacy and safety of peginterferon ...

Detailed Description

With nearly 4 million people in the United States, and an estimated 170-200 million people worldwide, the hepatitis C virus (HCV) represents a clear and significant public health issue. Unfortunately,...

Eligibility Criteria

Inclusion

  • Age: 18-50 years, with or without symptoms
  • Diagnosis of acute hepatitis C: elevated serum alanine aminotransferase (ALT) \> 10 times the upper limit of normal (ULN)
  • Seroconversion from negative to positive anti-HCV antibody status (third-generation enzyme-linked immunosorbent assay)
  • Conversion from negative to positive polymerase chain reaction (PCR) for HCV-RNA, ruling out other causes of hepatitis by history and appropriate serologic and virologic studies.

Exclusion

  • Decompensated liver disease
  • Coinfection with human immunodeficiency virus (HIV) or Schistosoma mansoni
  • Marked anemia (hemoglobin level ≤ 120 g/L in women and ≤ 130 g/L in men)
  • Neutropenia (\< 1,500/mm3)
  • Thrombocytopenia (\< 90,000/mm3)
  • A creatinine concentration \> 1.5 times ULN
  • Serum alpha-fetoprotein \> 25 ng/ml
  • An organ transplant
  • Neoplastic disease
  • Severe cardiac or pulmonary disease
  • Unstable thyroid dysfunction
  • A psychiatric disorder
  • Seizure disorder
  • Severe retinopathy
  • A current pregnancy or were breast feeding or unwillingness to practice contraception
  • Therapy with immunomodulatory agents within the last 6 months
  • Alcohol or drug dependence within 1 year of study entry.

Key Trial Info

Start Date :

January 1 2002

Trial Type :

INTERVENTIONAL

End Date :

January 1 2006

Estimated Enrollment :

180 Patients enrolled

Trial Details

Trial ID

NCT00241618

Start Date

January 1 2002

End Date

January 1 2006

Last Update

September 11 2006

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

ASU Specialized Hospital

Cairo, Cairo Governorate, Egypt, 11351

2

ASU

Cairo, Egypt, 03316

3

Shebin Liver Center

Cairo, Egypt, 11351